



For immediate release

23 May 2006

**ANGEL BIOTECHNOLOGY HOLDINGS PLC
("Angel" or "the Company")**

Successful completion of Chr. Hansen A/S contract

Angel Biotechnology Holdings plc, (AIM: ABH) the biopharmaceutical contract manufacturer, is pleased to announce the successful completion of a project for Chr. Hansen A/S, a company providing innovative ingredient solutions for the food, pharmaceutical, nutritional and agricultural industries. Using its proprietary High Throughput Screening system, Angel was able to double the yield of a key protein produced by one of Chr. Hansen's industrial production strains, significantly exceeding the target increase.

Gordon Sherriff, Chief Operating Officer of Angel Biotechnology Holdings plc, said: "We are delighted to have taken part in such a successful project with Chr. Hansen, achieving almost three times the target increase. The two companies have established an excellent working relationship and we hope to attract further projects from Chr. Hansen in the future."

Eric Johansen, Vice President, Molecular Microbiology of Chr. Hansen A/S, said: "Angel Biotechnology has provided an innovative and cost-effective solution to the problem of yield increase in our production organism. We are pleased with the quality of the project and will consider Angel for any similar projects in the future."

For further information, please call:

Angel Biotechnology Holdings plc
Gordon Sherriff – COO

Tel 01670 591920
Tel 07951 057016

Buchanan Communications
Lisa Baderoon/Mary-Jane Johnson

Tel 020 7466 5000

About Angel Biotechnology Holdings plc

Angel Biotechnology Holdings plc is a fast growing biomanufacturing company offering process development services and cGMP manufacturing to support biotechnology and pharmaceutical companies worldwide. Angel's principal activity is the manufacture and supply of materials for use in early stage drug development and pre-clinical studies, along with drug product and CMC documentation for Phases I, II and III clinical trials and the manufacture of licensed drugs or vaccines.

Angel is managed by a team that has more than 100 years' combined experience in pharmaceutical and biopharmaceutical manufacture, gained in companies such as Glaxo, SmithKline Beecham and Serologicals Inc.

Angel operates out of two sites, at Cramlington near Newcastle upon Tyne and at Pentlands Science Park, near Edinburgh.

Angel was established in 2000 and was admitted to trading on AIM in November 2005.

About Chr. Hansen A/S

Chr. Hansen develops innovative ingredient solutions for the food, pharmaceutical, nutritional and agricultural industries in close cooperation with its customers and partners.

The company's focus is to be a specialist in select industries and thereby provide the best ingredients for the industries we operate in. This gives our customers an essential competitive advantage. More about Chr Hansen: <http://www.chr-hansen.com/>